Preserved Antigen-Specific Immune Response in Patients with Multiple Sclerosis Responding to IFNβ-Therapy
Open Access
- 5 November 2013
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 8 (11) , e78532
Abstract
Interferon-beta (IFNβ) regulates the expression of a complex set of pro- as well as anti-inflammatory genes. In cohorts of MS patients unstratified for therapeutic response to IFNβ, normal vaccine-specific immune responses have been observed. Data capturing antigen-specific immune responses in cohorts of subjects defined by response to IFNβ-therapy are not available. To assess antigen-specific immune responses in a cohort of MS patients responding clinically and radiologically to IFNβ. In 26 MS patients, clinical and MRI disease activity were assessed before and under treatment with IFNβ. Humoral and cellular immune response to influenza vaccine was prospectively characterized in these individuals, and 33 healthy controls by influenza-specific Enzyme-Linked Immunosorbent Assay (ELISA) and Enzyme Linked Immuno Spot Technique (ELISPOT). Related to pre-treatment disease activity, IFNβ reduced clinical and radiological MS disease-activity. Following influenza vaccination, frequencies of influenza-specific T cells and concentrations of anti-influenza A and B IgM and IgG increased comparably in MS-patients and in healthy controls. By showing in a cohort of MS-patients responding to IFNβ vaccine-specific immune responses comparable to controls, this study indicates that antigen-specific immune responses can be preserved under successful IFNβ-therapy.Keywords
This publication has 22 references indexed in Scilit:
- Determinants of interferon β efficacy in patients with multiple sclerosisNature Reviews Neurology, 2011
- A type I interferon signature in monocytes is associated with poor response to interferon-β in multiple sclerosisBrain, 2009
- Interferon-β stabilizes barrier characteristics of the blood–brain barrier in four different species in vitroMultiple Sclerosis Journal, 2008
- Diminished Myelin-Specific T Cell Activation Associated with Increase in CTLA4 and Fas Molecules in Multiple Sclerosis Patients Treated with IFN- βJournal of Interferon & Cytokine Research, 2007
- Interferon-betaNeurology, 2007
- Defining the response to interferon‐β in relapsing‐remitting multiple sclerosis patientsAnnals of Neurology, 2006
- Drug Insight: interferon treatment in multiple sclerosisNature Clinical Practice Neurology, 2006
- The S1P-analog FTY720 differentially modulates T-cell homing via HEV: T-cell–expressed S1P1 amplifies integrin activation in peripheral lymph nodes but not in Peyer patchesBlood, 2005
- Complex immunomodulatory effects of interferon‐β in multiple sclerosis include the upregulation of T helper 1‐associated marker genesAnnals of Neurology, 2001
- The Type I Interferon Receptor: Structure, Function, and Evolution of a Family BusinessJournal of Interferon & Cytokine Research, 1999